Pretomanid and the BPaL Regimen

NOW INCLUDED IN THE WORLD HEALTH ORGANIZATION GUIDELINES FOR THE TREATMENT OF DRUG-RESISTANT TUBERCULOSIS

Pretomanid was developed by TB Alliance as an oral tablet formulation for the treatment of tuberculosis (TB) in combination with other anti-TB agents.

In August 2019, pretomanid received its first regulatory approval from the U.S. Food and Drug Administration (FDA) as part of a treatment regimen in combination with bedaquiline and linezolid, commonly called BPaL (bee-pal). The regimen was approved for the treatment of people with highly drug-resistant TB (DR-TB).



LEARN MORE ABOUT PRETOMANID'S DEVELOPMENT

1990


2000

2010

2020


SCAN ME

With critical support from funders, partners, and other stakeholders, TB Alliance developed pretomanid from a preclinical compound through a regulatory approval.





For the first time, almost all patients with DR-TB can be treated in six-months with an all-oral regimen. Based on clinical evidence, the new World Health Organization (WHO) guidelines allow for the implementation of treating almost all forms of DR-TB with either BPaL or BPaLM (a combination of bedaquiline, linezolid and pretomanid, with or without moxifloxacin).




READ THE WHO GUIDELINES



THE FUTURE OF TB TREATMENT

Prior to the introduction of BPaL, treatment of highly DR-TB was lengthy and complex. Most extensively drug-resistant TB (XDR-TB) patients took a combination of up to eight antibiotics for 18 months or longer, with little chance of curing their TB.





Favorable outcomes


DATA FROM TB ALLIANCE CLINICAL TRIALS HAVE SUPPORTED THE APPROVAL AND EXTENDED US OF BPAL




Nix-TB: An Open-Label, Single-Group Study








ZeNix: An Open-Label, Four-Group Study THE RESULTS






Group 1 *• *• *• *• *• Group 2


•• •• Bacteriological and Clinical Resolution Group 3 • • • • • 6 months after therapy Group 4








69.9-93.4 (95% CI)

HEAR THE #TBCOURAGE STORIES OF THOSE TREATED WITH BPAL











BESIK, cured with BPaL in Tbilisi